

220513US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

*Per Amndt
5/A
MLW*

IN RE APPLICATION OF :
LORENA MUGGETTI ET AL : ATTN: APPLICATION DIVISION
SERIAL NO: NEW U.S. PCT APPLN :
(Based on PCT/EP00/08983)
FILED: HEREWITH :
FOR: FORMULATIONS FOR
PARENTERAL USE OF
ESTRAMUSTINE PHOSPHATE
AND AMINO ACIDS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows:

AI 3. (Amended) A formulation according to claim 1 wherein estramustine phosphate is in the form of a pharmaceutically acceptable salt for parenteral use.

Ad 6. (Amended) A formulation according to claim 1 comprising estramustine phosphate and arginine in a molar ratio lower than 1:1.